Omega Healthcare Investors (OHI) opened 2026 with Q1 revenue of US$323 million and basic EPS of US$0.47, alongside funds from operations of US$249 million and FFO per share of US$0.84, setting a clear snapshot of cash generation and earnings at the start of the year. Over the past reported quarters, revenue has moved from US$277 million in Q1 2025 to US$319 million in Q4 2025 and EPS has ranged between US$0.34 and US$0.60 over that period. This gives investors a recent history of how the top line and per share earnings have tracked into the current release. With trailing twelve month net income and margins higher than a year ago, the latest numbers keep the focus firmly on how efficiently Omega is converting its rental streams into bottom line profit.

See our full analysis for Omega Healthcare Investors.

With the headline figures on the table, the next step is to see how these results line up with the prevailing narratives around Omega Healthcare Investors, highlighting where the numbers back the story and where they start to push against it.

Margins Near 50% Put Profitability in Focus

• Over the last 12 months, Omega reported net income of US$615.9 million on US$1.24b of revenue, giving a trailing net margin of 49.7% compared with 40.1% a year earlier.
• Consensus narrative points to demographic tailwinds and policy support for skilled nursing, and the current 49.7% margin and Q1 2026 net income of US$139.7 million show how a relatively small revenue base can translate into sizeable profit, while also raising the question of how resilient those margins would be if reimbursement terms or tenant health weaken.
  • The trailing earnings growth rate of 41.2% over the last year is stronger than the 9.7% per year five year average, which lines up with the idea that recent conditions have been supportive for operators and rent coverage.
  • At the same time, revenue forecasts pointing to about a 1.5% decline per year over the next three years test the bullish view that occupancy and reimbursement trends alone can sustain this level of profitability.

On margins this high, it pays to understand exactly what bulls point to as durable and what might prove temporary, and the full bullish narrative sets out those arguments in more detail 🐂 Omega Healthcare Investors Bull Case.

Funds From Operations Near US$965 Million

• On a trailing basis, FFO stands at US$964.6 million with FFO per share at US$3.27, compared with Q1 2026 quarterly FFO of US$249.5 million and FFO per share of US$0.84, which are key cash style metrics for a healthcare REIT.
• Bears highlight tenant credit risk, including concerns around operators under pressure, yet the trailing FFO and a reported dividend yield of 5.71% show that cash generation currently supports both rent collections and distributions, even as straight line rent accounting and potential reimbursement changes keep future FFO growth in question.
  • Over 80% of operator revenues being recognized on a straight line basis means annual rent escalators may not flow directly into adjusted FFO growth, which speaks to the bearish view that headline rent increases will not automatically show up as higher distributable cash.
  • Risks around tenant specific events such as the Genesis bankruptcy and exposure to U.K. regulation and currency make the durability of that roughly US$965 million FFO stream a central part of the cautious case.

If you are weighing the cash flow story against these tenant and reimbursement concerns, it is worth seeing how skeptics frame the risk reward trade off in their bear case 🐻 Omega Healthcare Investors Bear Case.

P/E of 22.8x and DCF Gap to US$91.77

• With a current share price of US$46.98, Omega trades on a trailing P/E of 22.8x, which is below the stated peer average of 84.8x and the industry average of 24.5x, and below a quoted DCF fair value of US$91.77, while analysts have a separate price target of US$49.63.
• Consensus narrative suggests the company is broadly fairly priced on analyst targets, and the small gap between US$46.98 and the US$49.63 target sits alongside a much wider difference to the DCF fair value, so investors are asked to weigh stronger trailing earnings growth and improved margins against forecasts of roughly 3.8% annual earnings growth and modest revenue declines.
  • The 41.2% earnings growth over the last year contrasts with the 3.8% annual growth forecast, which helps explain why some may view the P/E of 22.8x and the DCF fair value gap as interesting while others focus more on the muted outlook.
  • Debt coverage by operating cash flow is flagged as a key risk, so the lower than peer P/E and the dividend yield of 5.71% come with the trade off of higher balance sheet sensitivity if operating cash generation slows.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Omega Healthcare Investors on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Does this mix of strong profitability and flagged risks match how you see Omega Healthcare Investors, or does it conflict with your read of the numbers? If you want to move quickly from headline impressions to your own grounded view, start by weighing the 5 key rewards and 1 important warning sign.

See What Else Is Out There

Omega Healthcare Investors combines high margins with debt and tenant concentration risks, alongside forecasts of modest earnings growth and slight revenue declines that may limit future flexibility.

If you want income without leaning so heavily on one operator group or debt profile, check out 12 dividend fortresses to compare alternative income ideas right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.